• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

Methyl 6-(trifluoromethyl)pyrimidine-4-carboxylate (CAS No. 1353101-38-8): A Key Intermediate in Modern Pharmaceutical Synthesis

Methyl 6-(trifluoromethyl)pyrimidine-4-carboxylate (CAS No. 1353101-38-8) is a highly valuable intermediate in the realm of pharmaceutical chemistry, playing a pivotal role in the synthesis of various bioactive compounds. Its molecular structure, characterized by a trifluoromethyl group and a pyrimidine core, endows it with unique chemical properties that make it indispensable in the development of innovative therapeutic agents.

The trifluoromethyl group, a defining feature of this compound, is renowned for its ability to enhance metabolic stability, improve binding affinity to biological targets, and increase the overall pharmacological efficacy of drug candidates. This attribute has made Methyl 6-(trifluoromethyl)pyrimidine-4-carboxylate a sought-after building block in medicinal chemistry, particularly in the design of small-molecule inhibitors and agonists.

In recent years, significant advancements have been made in leveraging this compound for the development of novel treatments for complex diseases. For instance, researchers have utilized its pyrimidine scaffold to create potent inhibitors targeting enzymes involved in cancer progression. The trifluoromethyl moiety plays a crucial role in modulating the electronic properties of these inhibitors, thereby optimizing their interactions with target proteins.

One notable application of Methyl 6-(trifluoromethyl)pyrimidine-4-carboxylate is in the synthesis of kinase inhibitors, which are widely used in oncology due to their ability to disrupt aberrant signaling pathways in cancer cells. Studies have demonstrated that incorporating the trifluoromethyl group into kinase inhibitor molecules can lead to improved selectivity and reduced off-target effects, making these drugs safer and more effective for patients.

The compound's versatility extends beyond oncology; it has also been employed in the development of antiviral and anti-inflammatory agents. The pyrimidine core serves as a privileged scaffold for designing molecules that can interact with viral proteases or inflammatory cytokines, while the trifluoromethyl group enhances their pharmacokinetic profiles. This dual functionality has opened up new avenues for therapeutic intervention against a range of diseases.

From a synthetic chemistry perspective, Methyl 6-(trifluoromethyl)pyrimidine-4-carboxylate offers a robust platform for exploring diverse chemical modifications. Its carboxylate moiety allows for further functionalization via esterification, amidation, or other coupling reactions, enabling the creation of structurally diverse derivatives. This flexibility is particularly valuable in drug discovery pipelines where rapid iteration and optimization are essential.

The growing interest in fluorinated compounds has further highlighted the importance of intermediates like Methyl 6-(trifluoromethyl)pyrimidine-4-carboxylate. Fluorochemistry has emerged as a critical discipline within pharmaceutical research, with fluorine atoms being incorporated into drug molecules to enhance their bioavailability, stability, and therapeutic activity. The trifluoromethyl group, in particular, has been extensively studied for its ability to improve drug-like properties without significantly altering the core pharmacophore.

In conclusion, Methyl 6-(trifluoromethyl)pyrimidine-4-carboxylate (CAS No. 1353101-38-8) represents a cornerstone intermediate in modern pharmaceutical synthesis. Its unique structural features and functional attributes make it an invaluable tool for medicinal chemists seeking to develop novel therapeutics. As research continues to uncover new applications and synthetic strategies involving this compound, its significance in drug discovery is poised to grow even further.

• 6345-43-3(4,6-dimethyl pyrimidine-4,6-dicarboxylate)
• 878742-59-7(2-(Trifluoromethyl)pyrimidine-4-carboxylic acid)
• 933721-99-4(6-(trifluoromethyl)pyrimidine-4-carboxylic acid)
• 612088-38-7(4,6-PYRIMIDINEDICARBOXYLIC ACID, MONOMETHYL ESTER)
• 73955-53-0(Methyl 6-methylpyrimidine-4-carboxylate)
• 657-53-4(2-Chloro-6-trifluoromethyl-pyrimidine-4-carboxylic acid)
• 952182-20-6(methyl 6-(trifluoromethyl)-1H-pyrrolo2,3-bpyridine-2-carboxylate)
• 306960-80-5(2-Chloro-6-(trifluoromethyl)-4-pyrimidinecarboxylic Acid)
• 155377-05-2(Methyl 6-(trifluoromethyl)picolinate)
• 878745-51-8(Methyl 2-(trifluoromethyl)pyrimidine-4-carboxylate)